Search Medical Condition
Please enter condition
Please choose location from dropdown

Vaginitis Clinical Trials

A listing of Vaginitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (37) clinical trials

Most women mistake Bacterial Vaginosis for the common yeast infection. Although some symptoms of BV and Yeast Infections are similar - there are two distinct characteristics of BV - Discharge (thin, white-gray) and Unpleasant Odor. Patient Inclusion Criteria: If you are currently experiencing what you think are yeast infection symptoms, ...

Phase N/A

The goal of this study is to compare changes in the female genital tract in women diagnosed with bacterial vaginosis (BV) before and after treatment and to compare differences in the female genital tract in adolescent and adult women. Women with BV have an increased risk of acquiring HIV and ...

Phase

Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis

This is a Randomized, Positive -Controlled, Multi-center Trial enrolling 240 subjects with Bacterial Vaginosis who will be randomized at a ratio of 1:1 to receive active Honghe Fujie lotion or Metronidazole Suppositories. The primary objective is to assess the safety and tolerability of Honghe Fujie lotion compared to Metronidazole Suppositories.

Phase

Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy

Introduction Atrophic vaginitis is a condition that affects the majority of postmenopausal women. It is characterized by dryness and inflammation of the vagina, with thinning of the vaginal tissues. Atrophic vaginitis is caused by the decreased effect of estrogens post menopause. This condition becomes more significant over time, as systemic ...

Phase

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who ...

Phase

Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis

Background Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age, with an estimated prevalence of 29% in the general population of women aged 14 to 49 years. Women with symptomatic BV may present with malodorous discharge that is off-white, thin, and homogenous and has ...

Phase

Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis

Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the U.S. and has been associated with complications including preterm delivery of infants, pelvic inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV). Control of BV has ...

Phase

Vaginal and Urinary Microbiome Trial

This is a study is looking at the effects of vaginal estrogen and a nonhormonal alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause with the primary objective is to describe the bacterial communities associated in the vagina and urine of postmenopausal women receiving treatment ...

Phase

Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota

The vaginal microbiota is an important biological barrier for host against pathogens or opportunistic pathogens. Undermining the balance of the vagina is closely related to infectious diseases and tumors. The vaginal microbiota of child-bearing women of age is dominated by Lactobacillus species, including major four species: Lactobacillus crispatus, Lactobacillus jensenii, ...

Phase N/A

ProF-001_Phase IIa

This is a multi-center, randomized, prospective, active-controlled, double-blind, dose-escalation study comparing dose response of clinical efficacy, safety, local tolerability of three different doses of ProF-001/Candiplus (Candiplus 0.2%, Candiplus with 0.3%, Candiplus with 0.4%) to 1% clotrimazole vaginal cream. Patients with acute episode of vulvovaginal candidiasis (VVC) will be randomized to ...

Phase